Healthcare / BiotechnologyStockholm
$0.09
-0.01 (-10.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-18.6M · quality 80.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$116M
P/E
N/A
•EV/EBITDA
N/A
•ROE
5704.5%
↑Gross Margin
109.3%
↑Debt/Equity
-5.44
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-26.6%
FCF CAGR
—
FCF margin
-1007.4%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.6M · net income $-26.8M · FCF $-16.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.6M | $1.6M | $2.9M | $4.4M | $4.1M |
| Net Income | $-26.8M | $-26.8M | $-34.6M | $-37.3M | $-24.4M |
| EBITDA | $-14.5M | $-14.5M | $-17.6M | $-22.4M | $-18.0M |
| EPS | -0.04 | -0.04 | -0.10 | -0.16 | -0.17 |
| Gross Margin | 109.3% | 109.3% | 42.1% | 46.1% | -18.2% |
| Operating Margin | -1830.5% | -1830.5% | -1201.2% | -841.4% | -604.3% |
| Net Margin | -1660.1% | -1660.1% | -1197.4% | -856.8% | -598.6% |
| Balance Sheet | |||||
| Debt/Equity | -5.44 | -5.44 | 0.36 | 0.10 | 0.09 |
| Current Ratio | 0.99 | 0.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-16.3M | $-16.3M | $-18.6M | $-38.0M | $-40.6M |
| Returns | |||||
| ROE | 5704.5% | 5704.5% | -613.5% | -145.6% | -106.0% |
| Valuation | |||||
| P/B | — | — | 7.28 | 2.05 | 1.64 |
| Growth & Yield | |||||
| Revenue Growth | -44.1% | -44.1% | -33.6% | 6.7% | — |
| EPS Growth | 57.2% | 57.2% | 39.1% | 4.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.10 → -0.04
Residual
+9.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.